Metabolic Responses to Spermidine Supplementation.

Healthy Subjects Clinical Trial

Official title:

Randomized, Double-Blind, Crossover Study to Assess the Effects of a Spermidine Supplement on Metabolomics in Older Men

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05459961
• Other study ID #: BIO2203
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 14, 2022
• Est. completion date: February 2024

Study information

• Verified date: June 2023
• Source: Chrysea Labs Lda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Spermidine is naturally present in cells, organs, circulating cardiovascular system, and as part of our normal dietary intake. Studies suggest Spermidine is involved in antioxidation, autophagy, apoptosis, and immune regulation. Spermidine is typically present in foods of plant origin, such as natto, beans, fruits, vegetables, cheese, potatoes, bread, and cereals. Adequate spermidine dietary intake is important, given evidence of declining spermidine levels with age in humans and other species, and the evidence for positive effects of spermidine supplementation on age related biology. To date, human research studies utilised extracts containing low levels of spermidine (< 10%) and multiple other constituents, but this study will use pure spermidine to explore relevant mechanisms of action, biological effects, and identify potential biomarkers of positive biological effects.

Description:

This is a placebo controlled, double blind, randomised, within subject controlled study of supplementation with oral spermidine or placebo each for up to four weeks. The primary objective of this exploratory study is to examine the safety and biological effects of this pure full-dose spermidine supplement on metabolomics, inflammatory and metabolic markers, and transcriptomics. Study subjects are generally healthy males aged 50-70 After screening, subjects will enter a two week run-in (stabilisation) phase and then be randomised to blinded active or placebo for the first one week supplementation period. After a washout period, subjects will receive either blinded placebo or active for a second supplementation period of up to four weeks. The full study will require six visits by each study subject to the study site over a period of nine weeks, for blood and urine samples, and dietary intake assessments. Subjects are required to maintain a normal consistent dietary intake during the study and abstain from alcohol in the 24 hours before study visits. Assays include routine haematology and chemistry, CRP (C reactive protein), lipid screen, serum and urine metabolomics and polyamines, lipidomics, transcriptomics, and autophagy assays.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 42
• Est. completion date: February 2024
• Est. primary completion date: December 25, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

Caucasian men, 50-70 years of age Non-user or former users (cessation =6 months) of nicotine products (e.g., cigarettes, chewing tobacco) during the study period. Non-user or former users (cessation =6 months) of any marijuana or hemp products and no plans to use marijuana or hemp products during the study period Willing to maintain physical activity and exercise patterns, body weight, and habitual diet throughout the trial. No health conditions that would prevent the subject from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history, physical examination, and routine laboratory test results. Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator. Exclusion Criteria: Abnormal laboratory test results of clinical significance Clinically important gastrointestinal (GI) condition that would potentially interfere with the evaluation of the study product Type I or Type II diabetes mellitus. Uncontrolled pulmonary (including uncontrolled asthma), cardiac, hepatic, renal, endocrine, hematologic, immunologic, or neurologic disease. Had a positive SARS-CoV2 (COVID) test and experienced symptoms for > 2 months (i.e. long COVID) Has a condition the Clinical Investigator believes would interfere with ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Dietary Supplement:
• oral spermidine
oral supplement

Locations

Country	Name	City	State
United States	Biofortis Innovation Services	Addison	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Chrysea Labs Lda

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of molecular biology and bioeffect signalling using untargeted and targeted Metabolomics	Targeted analysis of spermidine, other polyamines, and approximately 250 other biomarkers, including lipids, lipoproteins, cholesterol and cholesterol esters, triglycerides, phospholipids, fatty acids and apolipoproteins using both mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy detection technology.; Untargeted analysis of small molecule biomarkers of both human genomic and microbiome origin using MS detection.; The metabolite profiles of each participant will be tracked longitudinally during the study and changes to targeted or untargeted metabolite profiles occurring between visits due to supplementation or washout from treatment will be evaluated.	Baseline, one week, and one month. Change will be evaluated between: (i) baseline, (ii) post-1 week, (iii) post washout crossover baseline, (iv) post 1 week, and (v) post 4 weeks.
Secondary	Serum lipidomics	targeted	baseline, one week, and one month
Secondary	CRP marker of inflammatory activity	C reactive protein	baseline, and one month
Secondary	Urinary untargeted and targeted metabolomics. Evaluation of molecular biology and bioeffect signalling and biomarker assessment	Targeted analysis for small molecule biomarkers of human genomic, dietary and microbiome origin including amino acids (human), 2-furoylglycine (dietary), 3-hydroxyhippurate (microbial metabolism) and approximately 50 others using nuclear magnetic resonance (NMR) detection technology. Untargeted analysis of small molecule biomarkers of human genomic, dietary and microbiome origin using mass spectrometry (MS) and NMR spectroscopy detection.	Baseline, one week, and one month. Change will be evaluated between: (i) baseline, (ii) post-1 week, (iii) post washout crossover baseline, (iv) post 1 week, and (v) post 4 weeks.
Secondary	Polyamine levels in urine and blood	Polyamine levels at each study visit	baseline, one week, and one month
Secondary	Autophagy assay	Western blot and Elisa assay	baseline and one week